Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Tezacaftor/Ivacaftor in Cystic Fibrosis
NCT02565914Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Aug 2015; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02565914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02565914.